Sotyktu (Deucravacitinib)
- Medicine Name: Sotyktu
- Generic Name: Deucravacitinib
- Dosage Form & Strength: Tablets: 6 mg
- Manufactured By: Bristol Myers Squibb
Sotyktu (deucravacitinib) is a tyrosine kinase 2 (TYK2) inhibitor used for the treatment of adult individuals with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Limitations of Use: This medicinal product is not recommended for use in conjunction with other potent immunosuppressants.
Recommended Dosage: Evaluate individuals for active as well as latent tuberculosis (TB) infection before starting Sotyktu treatment. If positive, initiate treatment for tuberculosis prior to the use of this therapy. Update immunizations as per current immunization guidelines.
The recommended dosage of Sotyktu tablet is 6 mg taken orally once daily, with or without food. Do not chew, crush, or cut the pills. This medicinal product is not recommended for those with severe hepatic impairment (Child-Pugh C).
- Hypersensitivity reactions such as angioedema may occur in subjects receiving Sotyktu therapy. In case of clinically significant hypersensitivity reaction, institute apt therapy and discontinue treatment with Sotyktu.
- Sotyktu may be responsible for increasing the risk of infections. Avoid use of this medication in those with an active or severe infection. Precisely monitor individuals for the development of signs and/or symptoms of infection throughout and after therapy with Sotyktu tablets.
- Consider anti-TB therapy before initiation of Sotyktu 6 mg tablets in patients with a past history of latent or active TB in whom an apt course of therapy cannot be confirmed. Evaluate patients receiving this treatment for signs and/or symptoms of active TB throughout the treatment.
- Malignancies, including lymphomas, may occur with Deucravacitinib. Consider the benefits and risks for the individual patient before starting or continuing treatment, particularly those with a known malignancy and those who establish a malignancy when on Deucravacitinib treatment.
- Before initiating treatment with Deucravacitinib, complete all age-appropriate immunizations as per current immunization guidelines including prophylactic herpes zoster vaccination. Do not use live vaccines in those treated with this medicine. The response to live or non-live vaccines yat to be assessed.
What documents are required to import SOTYKTU to India?
SOTYKTU (deucravacitinib) tablets can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients ID proof (issued by the government of India)
The order will be confirmed only after the receipt of:
- A valid prescription from Doctor
- Import permit if applicable
SOTYKTU (deucravacitinib tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
- On availability of Sotyktu in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency
IPN (Indian Pharma Network) can facilitate the supply of SOTYKTU (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).
Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Sotyktu 6 mg price in India.
We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
What is the Generic Name for the trade name drug Sotyktu®?
Deucravacitinib is a Generic Name for the trade name drug Sotyktu®.
What is the Manufacturer’s Name of Sotyktu®?
Sotyktu® is manufactured by Bristol Myers Squibb.
Is Sotyktu® approved by the FDA?
Yes, Sotyktu® is approved by the FDA. Date of approval: September 9, 2022.
Where can I get Sotyktu® at the best price in India?
To get the best Sotyktu price in India, kindly connect with the Indian Pharma Network (a WHO GDP & ISO 9001:2008 certified company). For Sotyktu®, a medical prescription is required from a treating physician.
What is the dosage and form of Sotyktu® supplied?
Sotyktu® is supplied as Tablets: 6 mg for oral administration.
What are the most commonly reported side effects of Sotyktu®?
The most commonly reported side effects of Sotyktu® are blood creatine phosphokinase increased, acne, herpes simplex, upper respiratory infections, folliculitis, and mouth ulcers.
How much does Sotyktu® cost in India?
The cost of Sotyktu in India can vary. In order to procure this TYK2 inhibitor legally, you can Call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Sotyktu®?
Store the tablets of Sotyktu at room temperature between 68 to 77°F (20 to 25°C).
Is it safe to buy Sotyktu® online in India?
Yes, one can buy Sotyktu online in India at the lowest price from the Indian Pharma Network (IPN) if the medicine Sotyktu® is not (yet) registered or available in your country. We can help facilitate the supply of Sotyktu® through legal channels.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.